Literature DB >> 11005558

Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

T F Wood1, D M Rose, M Chung, D P Allegra, L J Foshag, A J Bilchik.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is increasingly used for the local destruction of unresectable hepatic malignancies. There is little information on its optimal approach or potential complications.
METHODS: Since late 1997, we have undertaken 91 RFA procedures to ablate 231 unresectable primary or metastatic liver tumors in 84 patients. RFA was performed via celiotomy (n = 39), laparoscopy (n = 27), or a percutaneous approach (n = 25). Patients were followed with spiral computed tomographic (CT) scans at 1 to 2 weeks postprocedure and then every 3 months for 2 years.
RESULTS: Intraoperative ultrasound (IOUS) detected intrahepatic disease not evident on the preoperative scans of 25 of 66 patients (38%) undergoing RFA via celiotomy or laparoscopy. In 38 of 84 patients (45%), RFA was combined with resection or cryosurgical ablation (CSA), or both. RFA was used to treat an average of 2.8 lesions per patient, and the median size of treated lesions was 2 cm (range, 0.3-9 cm). The average hospital stay was 3.6 days overall (1.8 days for percutaneous and laparoscopic cases). Ten patients underwent a second RFA procedure (sequential ablations) and, in one case, a third RFA procedure for large (one patient), progressive (seven patients), and/or recurrent (three patients) lesions. Seven (8%) patients had complications: one skin burn; one postoperative hemorrhage; two simple hepatic abscesses; one hepatic abscess associated with diaphragmatic heat necrosis following sequential percutaneous ablations of a large lesion; one postoperative myocardial infarction; and one liver failure. There were three deaths, one (1%) of which was directly related to the RFA procedure. Three of the complications, including one RFA-related death, occurred after percutaneous RFA. At a median follow-up of 9 months (range, 1-27 months), 15 patients (18%) had recurrences at an RFA site, and 36 patients (43%) remained clinically free of disease.
CONCLUSIONS: Celiotomy or laparoscopic approaches are preferred for RFA because they allow IOUS, which may demonstrate occult hepatic disease. Operative RFA also allows concomitant resection, CSA, or placement of a hepatic artery infusion pump, and isolation of the liver from adjacent organs. Percutaneous RFA should be reserved for patients at high risk for anesthesia, those with recurrent or progressive lesions, and those with smaller lesions sufficiently isolated from adjacent organs. Complications may be minimized when these approaches are applied selectively.

Entities:  

Mesh:

Year:  2000        PMID: 11005558     DOI: 10.1007/bf02725339

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  113 in total

1.  Fatal bile pulmonary embolism after radiofrequency treatment of a hepatocellular carcinoma.

Authors:  C Schmidt-Mutter; T Breining; A Gangi; E Canela; I Jourdan; D Mutter; J-P Dupeyron
Journal:  Surg Endosc       Date:  2003-10-28       Impact factor: 4.584

2.  Radioembolization for hepatocellular carcinoma complicated by biliary stricture.

Authors:  Jeet Minocha; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

3.  Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs.

Authors:  Maria A Cassera; Kevin W Potter; Michael B Ujiki; Lee L Swanström; Paul D Hansen
Journal:  Surg Endosc       Date:  2010-09-17       Impact factor: 4.584

Review 4.  Complications of intraoperative radiofrequency ablation of liver metastases.

Authors:  Tsiriniaina Razafindratsira; Milène Isambert; Serge Evrard
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

5.  Radiofrequency ablation for hepatocellular carcinoma: use of low vs maximal radiofrequency power.

Authors:  T C Macatula; C-C Lin; C-J Lin; W-T Chen; S-M Lin
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

6.  Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients.

Authors:  Timothy M Pawlik; Francesco Izzo; Deborah S Cohen; Jeffery S Morris; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2003-11       Impact factor: 5.344

7.  Radiofrequency (RF)-assisted hepatectomy may induce severe postoperative liver damage.

Authors:  Miyazawa Mitsuo; Torii Takahiro; Toshimitsu Yasuko; Aikawa Masayasu; Okada Katsuya; Shinozuka Nozomi; Otani Yoshihide; Koyama Isamu
Journal:  World J Surg       Date:  2007-09-18       Impact factor: 3.352

Review 8.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Management of hepatic metastases from colorectal cancer.

Authors:  Ketan R Sheth; Bryan M Clary
Journal:  Clin Colon Rectal Surg       Date:  2005-08

10.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.